Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
Not yet recruitingOBSERVATIONAL
Enrollment
278
Participants
Timeline
Start Date
October 9, 2025
Primary Completion Date
June 30, 2028
Study Completion Date
December 31, 2028
Conditions
Unresectable Hepatocellular Carcinom
All Listed Sponsors
lead
Shanghai Zhongshan Hospital
OTHER
NCT07206511 - Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study | Biotech Hunter | Biotech Hunter